Document ID: chunk:federal_register_of_legislation:F2025C00151:body:0:p2
Version: federal_register_of_legislation:F2025C00151
Segment Type: other
Provision Reference: 
Character Range: 3392–9062

docosahexaenoic acid (DHA)  section S3—13

2′-fucosyllactose sourced from Corynebacterium glutamicum  section S3—51

2′-fucosyllactose sourced from Escherichia coli BL21                                                                                                                                     section S3—45
2′-fucosyllactose sourced from Escherichia coli K-12 containing the gene for alpha-1,2-fucosyltransferase from either Heliobacter enhydrae, Helicobacter pylori or Bacteroides vulgatus  section S3—40

2′-fucosyllactose and difucosyllactose sourced from Escherichia coli K-12  section S3—47

lacto-N-tetraose sourced from Escherichia coli K-12                        section S3—48
6′-sialyllactose sodium salt sourced from Escherichia coli K-12            section S3—49
3′-sialyllactose sodium salt sourced from Escherichia coli K-12            section S3—50

ice structuring protein type III HPLC 12 preparation                                                       section S3—14
isomalto-oligosaccharide                                                                                   section S3—37
Isomaltulose                                                                                               section S3—15
lacto-N-neotetraose                                                                                        section S3—41
L-arginine acetate                                                                                         section S3—38
Listeria phage P100                                                                                        section S3—16
2-Methyloxolane                                                                                            section S3—52
Nicotinamide riboside chloride                                                                             section S3—44
nucleotides                                                                                                sections S3—17 and S3—18
oil derived from marine micro-algae Schizochytrium sp. (American Type Culture Collection (ATCC) PTA-9695)  section S3—36
oil derived from marine micro-algae (Schizochytrium sp.) rich in docosahexaenoic acid (DHA)                section S3—21
oil derived from marine micro-algae (Ulkenia sp.) rich in docosahexaenoic acid (DHA)                       section S3—22
oil derived from the algae Crypthecodinium cohnii rich in docosahexaenoic acid (DHA)                       section S3—19
oil derived from the fungus Mortierella alpina rich in arachidonic acid (ARA)                              section S3—20
oxidised polyethylene                                                                                      section S3—23
phytosterols, phytostanols and their esters                                                                section S3—24
quaternary amine cellulose ion exchange resin                                                              section S3—25
rapeseed protein isolate                                                                                   section S3—39(A)
resistant maltodextrins                                                                                    section S3—26
Salmonella phage preparation (S16 and FO1a)                                                                section S3—33
steviol glycosides from fermentation                                                                       section S3—39
steviol glycosides produced by enzymatic conversion                                                        section S3—35
soy leghemoglobin preparation                                                                              section S3—42
sulphonate agarose ion exchange resin                                                                      section S3—34
Sweet osmanthus ear glycolipids                                                                            section S3—43
tall oil phytosterol esters                                                                                section S3—27
yeast—enriched selenium                                                                                    section S3—28
yeast—high chromium                                                                                        section S3—29
yeast—high molybdenum                                                                                      section S3—30

S3—3 Substances with specifications in secondary sources
  If there is no relevant specification under section S3—2, the specification is a specification listed in one of the following:
 (a) British Pharmacopoeia Commission (2014) British Pharmacopoeia 2014. TSO, Norwich;
 (b) United States Pharmacopeial Convention (2020) United States Pharmacopeia (43) and the National Formulary (38), (USP 43-NF 38). United States Pharmacopeial Convention, Rockville, MD;
 (c) Royal Pharmaceutical Society of Great Britain. Lund W (1994) Pharmaceutical codex: principles and practice of pharmaceutics, 12th ed, Pharmaceutical Press, London;
 (d) Sweetman SC (2011) Martindale: the complete drug reference. 37th ed, Pharmaceutical Press, London;
 (e) the European Pharmacopoeia 8th Edition, Council of Europe, Strasbourg (2014);
 (f) the International Pharmacopoeia 4th Edition, World Health Organization, Geneva (2006 and 2008 supplement);
 (g) the Merck Index, 15th Edition, (2013);
 (h) the Code of Federal Regulations;
 (i) the Specifications and Standards for Food Additives, 9th Edition (2018)', Ministry of Health and Welfare (Japan); or
 (j) the International Oenological Codex (2022), Organisation Internationale de la Vigne et du Vin (OIV).
S3—4 Additional and supplementary